Marci Lee Nilsen1,2,3, Leila J Mady1, Jacob Hodges4, Tamara Wasserman-Wincko1, Jonas T Johnson1. 1. Department of Otolaryngology, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania, U.S.A. 2. Department of Acute and Tertiary Care, Pittsburgh, Pennsylvania, U.S.A. 3. The University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania, U.S.A. 4. UPMC Wolff Center, Pittsburgh, Pennsylvania, U.S.A.
Abstract
OBJECTIVE: With the intensification and utilization of multimodal treatment, acute toxicities have increased; however, the frequency of treatment sequelae in long-term head and neck cancer (HNC) survivors are poorly described. The purpose of this analysis was to determine the prevalence and predictors of patient-reported late and long-term treatment-related sequelae in HNC survivors. METHODS: We performed a cross-sectional analysis of patient-reported outcomes from 228 survivors attending a multidisciplinary HNC survivorship clinic. The primary outcomes comprised quality of life (QOL), symptoms of anxiety and depression, and swallowing dysfunction. RESULTS: Male gender, tumor sites in the oropharynx and larynx, longer time since treatment, and treatment with surgery alone were associated with higher physical QOL (P < .05). Male gender, longer time since treatment, and treatment with surgery alone were associated with higher social-emotional QOL (P < .05). A reduction in anxiety symptoms and a higher QOL were related to longer time since treatment; however, a reduction in swallowing dysfunction symptoms was only related to longer time since treatment until approximately 6 years. After 6 years, survivors reported worse swallowing dysfunction (P < .05). One hundred thirty-two survivors (56%) reported at least three treatment-related effects that impacted their daily life. Finally, advanced stage disease at diagnosis (stage III-IV) was also associated with severe swallowing dysfunction (P = .004). CONCLUSION: These data indicate the remarkable prevalence of treatment-related effects in HNC survivors. These results highlight the need for de-intensification of therapies, where appropriate, and for a better understanding of pathophysiology and new approaches to mitigating treatment effects. LEVEL OF EVIDENCE: 4 Laryngoscope, 129:E437-E444, 2019.
OBJECTIVE: With the intensification and utilization of multimodal treatment, acute toxicities have increased; however, the frequency of treatment sequelae in long-term head and neck cancer (HNC) survivors are poorly described. The purpose of this analysis was to determine the prevalence and predictors of patient-reported late and long-term treatment-related sequelae in HNC survivors. METHODS: We performed a cross-sectional analysis of patient-reported outcomes from 228 survivors attending a multidisciplinary HNC survivorship clinic. The primary outcomes comprised quality of life (QOL), symptoms of anxiety and depression, and swallowing dysfunction. RESULTS: Male gender, tumor sites in the oropharynx and larynx, longer time since treatment, and treatment with surgery alone were associated with higher physical QOL (P < .05). Male gender, longer time since treatment, and treatment with surgery alone were associated with higher social-emotional QOL (P < .05). A reduction in anxiety symptoms and a higher QOL were related to longer time since treatment; however, a reduction in swallowing dysfunction symptoms was only related to longer time since treatment until approximately 6 years. After 6 years, survivors reported worse swallowing dysfunction (P < .05). One hundred thirty-two survivors (56%) reported at least three treatment-related effects that impacted their daily life. Finally, advanced stage disease at diagnosis (stage III-IV) was also associated with severe swallowing dysfunction (P = .004). CONCLUSION: These data indicate the remarkable prevalence of treatment-related effects in HNC survivors. These results highlight the need for de-intensification of therapies, where appropriate, and for a better understanding of pathophysiology and new approaches to mitigating treatment effects. LEVEL OF EVIDENCE: 4 Laryngoscope, 129:E437-E444, 2019.
Authors: V C Sandulache; Y L Lei; L E Heasley; M Chang; C I Amos; E M Sturgis; E Graboyes; E Y Chiao; N Rogus-Pulia; J Lewis; A Madabhushi; M J Frederick; A Sabichi; M Ittmann; W G Yarbrough; C H Chung; R Ferrarotto; Weiyuan Mai; H D Skinner; U Duvvuri; P Gerngross; A G Sikora Journal: Oral Oncol Date: 2019-10-22 Impact factor: 5.337
Authors: Chindhu Shunmugasundaram; Haryana M Dhillon; Phyllis N Butow; Puma Sundaresan; Claudia Rutherford Journal: Qual Life Res Date: 2021-04-02 Impact factor: 4.147
Authors: Lori Zitelli; Catherine Palmer; Elizabeth Mamula; Jonas Johnson; Grant Rauterkus; Marci L Nilsen Journal: J Cancer Surviv Date: 2022-03-29 Impact factor: 4.442
Authors: Joaquin E Jimenez; Marci Lee Nilsen; William E Gooding; Jennifer L Anderson; Nayel I Khan; Leila J Mady; Tamara Wasserman-Wincko; Umamaheswar Duvvuri; Seungwon Kim; Robert L Ferris; Mario G Solari; Mark W Kubik; Jonas T Johnson; Shaum Sridharan Journal: Oral Oncol Date: 2021-10-26 Impact factor: 5.337
Authors: Marci Lee Nilsen; David A Clump; Mark Kubik; Karen Losego; Alyssa Mrozek; Elizabeth Pawlowicz; Debra Pickford; Shaum Sridharan; Katie Traylor; Tamara Wasserman-Wincko; Kelly Young; Dan Zandberg; Jonas T Johnson Journal: Head Neck Date: 2020-05-18 Impact factor: 3.147
Authors: Marianne Boll Kristensen; Irene Wessel; Anne Marie Beck; Karin B Dieperink; Tina Broby Mikkelsen; Jens-Jakob Kjer Møller; Ann-Dorthe Zwisler Journal: Nutrients Date: 2020-07-17 Impact factor: 5.717
Authors: Thomas M Kaffenberger; Ankur K Patel; Lingyun Lyu; Jinhong Li; Tamara Wasserman-Wincko; Dan P Zandberg; David A Clump; Jonas T Johnson; Marci L Nilsen Journal: Laryngoscope Investig Otolaryngol Date: 2021-09-16